An observational study in Dyslipidemia, sponsored by HK inno.N Corporation. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by HK inno.N Corporation · Observational
This study will be conducted under routine clinical practice. Rovazet tablets will be administered in accordance with the approved dosage and administration as part of standard clinical care for dyslipidemia. Data will be collected at up to three time points from study enrollment through Week 48: baseline, Week 24, and Week 48.
This study is designed as a multicenter, prospective study to evaluate the effectiveness and safety of Rovazet tablets in patients diagnosed with dyslipidemia for whom treatment with Rovazet has been determined under routine clinical practice.
During routine clinical visits, the investigator will determine whether treatment with Rovazet tablets is appropriate for patients diagnosed with dyslipidemia. In the course of routine clinical care, the investigator will determine the dose and prescribe Rovazet tablets in accordance with the product labeling. The medication to be administered to the participant must be determined before the participant provides consent to participate in the study and without any intervention related to the study.
1,247 studies on the registry are indexed under Dyslipidemias; 175 are open to participants now.
This study's planned enrollment of 6,713 is above the median of 648 across 229 observational studies indexed under Dyslipidemias.
Browse Dyslipidemias studies →HK inno.N Corporation is the lead sponsor of 102 studies on the registry; 17 are open to participants now.
Counted across the registry records on this site, refreshed daily.
6,713
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The proportion of study participants who achieve the LDL-C treatment target at Week 24, according to the dyslipidemia treatment guidelines
LDL-C treatment targets in the fifth edition of the Korean Society of Lipid and Atherosclerosis clinical practice guidelines
Time frame: Day 1 to week 24
The proportion of study participants who achieve the LDL-C treatment target at Week 48, according to the dyslipidemia treatment guidelines.
Time frame: Day 1 to week 48
The percentage change from baseline in lipid profile parameters (TC, TG, HDL-C, and LDL-C) at Week 24.
Percentage change (%) = \[(Lipid profile parameter at Week 24 - Lipid profile parameter at baseline) / Lipid profile parameter at baseline\] × 100
Time frame: Day 1 to week 24
The percentage change from baseline in lipid profile parameters (TC, TG, HDL-C, and LDL-C) at Week 48.
Percentage change (%) = \[(Lipid profile parameter at Week 48 - Lipid profile parameter at baseline) / Lipid profile parameter at baseline\] × 100
Time frame: Day 1 to week 48
Medication adherence
Assessed using the medication possession ratio (MPR)
Time frame: Day 1 to week 48
Plan to share: No
No publications or documents are linked to this record.
Started May 2024 (actual). Primary completion is estimated for Dec 2028, 55 months after the start.
Of 34 industry-sponsored observational studies under Dyslipidemias, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 40. This study's planned 55 months is above that.
Counting every sponsor, half of 89 studies reached it within 40 months; a quarter within 23 and three quarters within 118.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.